Literature DB >> 23255544

The value of image-guided intensity-modulated radiotherapy in challenging clinical settings.

S J Treece1, M Mukesh, Y L Rimmer, S J Tudor, J C Dean, R J Benson, D L Gregory, G Horan, S J Jefferies, S G Russell, M V Williams, C B Wilson, N G Burnet.   

Abstract

OBJECTIVE: To illustrate the wider potential scope of image-guided intensity-modulated radiotherapy (IG-IMRT), outside of the "standard" indications for IMRT.
METHODS: Nine challenging clinical cases were selected. All were treated with radical intent, although it was accepted that in several of the cases the probability of cure was low. IMRT alone was not adequate owing to the close proximity of the target to organs at risk, the risk of geographical miss, or the need to tighten planning margins, making image-guided radiotherapy an essential integral part of the treatment. Discrepancies between the initial planning scan and the daily on-treatment megavoltage CT were recorded for each case. The three-dimensional displacement was compared with the margin used to create the planning target volume (PTV).
RESULTS: All but one patient achieved local control. Three patients developed metastatic disease but benefited from good local palliation; two have since died. A further patient died of an unrelated condition. Four patients are alive and well. Toxicity was low in all cases. Without daily image guidance, the PTV margin would have been insufficient to ensure complete coverage in 49% of fractions. It was inadequate by >3 mm in 19% of fractions, and by >5 mm in 9%.
CONCLUSION: IG-IMRT ensures accurate dose delivery to treat the target and avoid critical structures, acting as daily quality assurance for the delivery of complex IMRT plans. These patients could not have been adequately treated without image guidance. ADVANCES IN KNOWLEDGE: IG-IMRT can offer improved outcomes in less common clinical situations, where conventional techniques would provide suboptimal treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23255544      PMCID: PMC4651069          DOI: 10.1259/bjr.20120278

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  45 in total

1.  The implementation of intensity-modulated radiotherapy in the UK.

Authors:  M V Williams; T Cooper; R Mackay; J Staffurth; D Routsis; N Burnet
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-07-21       Impact factor: 4.126

2.  First quinquennial review of intensity-modulated radiotherapy at St Bartholomew's Hospital, London.

Authors:  D Smith; N MacDougall; J Monk; A Sibtain; M E Powell; P N Plowman
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-07-31       Impact factor: 4.126

3.  Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.

Authors:  Anurag K Singh; Perry W Grigsby; Janet S Rader; David G Mutch; Matthew A Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

4.  Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy.

Authors:  Daniel T T Chua; Jonathan S T Sham; Lucullus H T Leung; Gordon K H Au
Journal:  Radiother Oncol       Date:  2005-11-08       Impact factor: 6.280

Review 5.  Advances in image-guided radiation therapy.

Authors:  Laura A Dawson; David A Jaffray
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

Review 6.  Innovations in image-guided radiotherapy.

Authors:  Dirk Verellen; Mark De Ridder; Nadine Linthout; Koen Tournel; Guy Soete; Guy Storme
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

7.  Two-year clinical experience with tomotherapy: the French national cancer institute project on implementing new technology.

Authors:  Philippe Giraud; Guy Kantor; Michael Yassa; Sofia Zefkili; Catherine Dejean; Albert Lisbona; François Campana; Marc-André Mahé
Journal:  Cancer Invest       Date:  2011-08-15       Impact factor: 2.176

8.  Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).

Authors:  Ander Urruticoechea; Monica Arnedos; Geraldine Walsh; Mitch Dowsett; Ian E Smith
Journal:  Breast Cancer Res Treat       Date:  2007-09-13       Impact factor: 4.872

9.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

10.  Tomotherapy as a tool in image-guided radiation therapy (IGRT): theoretical and technological aspects.

Authors:  S Yartsev; T Kron; J Van Dyk
Journal:  Biomed Imaging Interv J       Date:  2007-01-01
View more
  2 in total

Review 1.  Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations.

Authors:  Sophie Dobiasch; Nicole L Goerig; Rainer Fietkau; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-11-01       Impact factor: 3.621

2.  Image guidance protocols: balancing imaging parameters against scan time.

Authors:  A M Bates; J E Scaife; G S J Tudor; R Jena; M Romanchikova; J C Dean; A C F Hoole; M P D Simmons; N G Burnet
Journal:  Br J Radiol       Date:  2013-10-15       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.